Drug General Information (ID: DDI7NXOAWL)
Drug Name			Asparaginase Escherichia coli		Drug Info		Lyme disease vaccine (recombinant OspA)		Drug Info
Drug Type		Protein/peptide				Vaccine
Therapeutic Class		Antineoplastics				Vaccine

Mechanism of Asparaginase Escherichia coli-Lyme disease vaccine (recombinant OspA) Interaction (Severity Level: Moderate)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Asparaginase Escherichia coli				Lyme disease vaccine (recombinant OspA)
Mechanism		Immunosuppressive effects				Vaccine or toxoid
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Lyme disease vaccine (recombinant OspA) when combined with Asparaginase Escherichia coli

Recommended Action
Management		The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).

References
1	Shen AK, Mead PS, Beard CB. The Lyme disease vaccine--a public health perspective. Clin Infect Dis. 2011;52 Suppl 3:s247-s252. [PMID: 21217171]